Michael Carson

Directeur Financier/CFO chez NUVECTIS PHARMA, INC.

Fortune : 613 856 $ au 31/05/2024

Health Technology

Commercial Services

Consumer Services

Relations actives

Nom	Sexe	Age	Sociétés liées	Collaboration
Ronald Bentsur	M	58	NUVECTIS PHARMA, INC.	4 ans
Shay Shemesh	M	41	NUVECTIS PHARMA, INC.	4 ans
Glenn Muir	M	65	NEURONETICS, INC.	7 ans
Matt Kaplan	M	56	NUVECTIS PHARMA, INC.	3 ans
Kenneth Hoberman	M	59	NUVECTIS PHARMA, INC.	3 ans
James Oliviero	M	48	NUVECTIS PHARMA, INC.	3 ans
Enrique Poradosu	M	58	NUVECTIS PHARMA, INC.	4 ans
Aidan King	M	53	Xylocor Therapeutics, Inc. Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.	3 ans

Relation dans plusieurs entreprises

Nom	Sexe	Age	Sociétés liées	Collaboration
Peter Donato	M	54	NEURONETICS, INC.	2 ans
Ron Hunt	M	59	NEURONETICS, INC.	4 ans
Paulina Hill	M	42	NEURONETICS, INC.	2 ans
Gregory Harper	M	63	NEURONETICS, INC.	5 ans
Paul Neff	M	72	NEURONETICS, INC.	9 ans
Mark Demitrack	M	66	NEURONETICS, INC.	14 ans
Daniel Guthrie	M	47	NEURONETICS, INC.	2 ans
Cassie Hallberg	F	-	NEURONETICS, INC.	3 ans
Yelena Tropsha	F	63	NEURONETICS, INC.	2 ans
Rick Trank	M	-	NEURONETICS, INC.	1 ans

Pays	Relations	% du total
Etats-Unis	18	100,00%

Age des relations

Actives

Passées

Homme

Femme

Administrateurs

Exécutifs

Provenance des relations